Free Trial

Altimmune (ALT) Earnings Date, Estimates & Call Transcripts

Altimmune logo
$3.14 +0.08 (+2.45%)
As of 10:22 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Altimmune Earnings Summary

Altimmune released Q4 2025 earnings on March 5, 2026, reporting an EPS of -$0.27, which missed analysts' consensus estimates of -$0.25 by $0.02. Quarterly revenue was reported to be $0.03 million, above analysts' expectations of $0 million. With a trailing EPS of -$1.01, Altimmune's earnings are expected to remain at ($1.00) per share in the coming year.

Upcoming
Earnings Date
May. 12Before Market OpensEstimated
Consensus EPS
(Mar. 5)
-$0.25
Actual EPS
(Mar. 5)
-$0.27 Missed By -$0.02
Actual Revenue
(Mar. 5)
$0.03M

Q4 2025 Earnings Resources

ALT Upcoming Earnings

Altimmune's Q1 2026 earnings is estimated for Tuesday, May 12, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get Altimmune Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Altimmune and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

ALT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ALT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Altimmune Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.35-$0.23-$0.29
Q2 20262-$0.35-$0.24-$0.30
Q3 20262-$0.35-$0.25-$0.30
Q4 20263-$0.38-$0.25-$0.31
FY 2026 9 -$1.43 -$0.97 -$1.20
Q1 20271-$0.28-$0.28-$0.28
Q2 20271-$0.30-$0.30-$0.30
Q3 20271-$0.32-$0.32-$0.32
Q4 20271-$0.30-$0.30-$0.30

Altimmune Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/12/2026
(Estimated)
--------
3/5/2026Q4 2025-$0.25-$0.2719 -$0.0219-$0.27$0.00M$0.03M
11/6/2025Q3 2025-$0.29-$0.21+$0.08-$0.21$0.00M$0.01M
8/12/2025Q2 2025-$0.32-$0.27+$0.05-$0.27$0.00M$0.01M
5/13/2025Q1 2025-$0.35-$0.26+$0.09-$0.26$0.00M$0.01M
2/27/2025Q4 2024-$0.34-$0.33+$0.01-$0.33$0.00M$0.01M
11/12/2024Q3 2024-$0.35-$0.32+$0.03-$0.32-$0.01M
8/8/2024Q2 2024-$0.34-$0.35 -$0.01-$0.35-$0.01M
5/9/2024Q1 2024-$0.36-$0.34+$0.02-$0.34-$0.01M

Data powered by Fiscal.ai.

Altimmune Earnings - Frequently Asked Questions

Altimmune has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 12th, 2026 based off last year's report dates. Learn more on ALT's earnings history.

In the previous quarter, Altimmune (NASDAQ:ALT) missed the analysts' consensus estimate of ($0.25) by $0.02 with a reported earnings per share (EPS) of ($0.27). Learn more on analysts' earnings estimate vs. ALT's actual earnings.

The conference call for Altimmune's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Altimmune's latest earnings report can be read online.
Read Transcript

Altimmune's earnings report can be found in their filing with the SEC.
View SEC filing

Altimmune (NASDAQ:ALT) has a recorded annual revenue of $40,000.00.

Altimmune (NASDAQ:ALT) has a recorded net income of -$88.09 million. ALT has generated -$1.01 earnings per share over the last four quarters.

Altimmune's earnings are expected to stay at ($1.00) per share in the next year.


This page (NASDAQ:ALT) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners